ad

3 Pharmaceuticals Company, Iron Ore Miner and Engineering Consultancy Company Stocks With a Strong Future Roadmap: Alembic Pharmaceuticals, NMDC and Engineers India

Alembic Pharmaceuticals, NMDC and Engineers India: ROE of 11.9% to 22.0% and FY22 to FY26 revenue CAGR of 5.9% to 8.4%. Prices as of 16 Nov 2026.


17 Nov 2026 • 2:42 pm

3 Pharmaceuticals Company, Iron Ore Miner and Engineering Consultancy Company Stocks With a Strong Future Roadmap: Alembic Pharmaceuticals, NMDC and Engineers India

Quick Answer

The three pharma, iron ore and consultancy stocks to watch are Alembic Pharmaceuticals, NMDC and Engineers India. Their return on equity ranges from 11.9% to 22.0%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.9% to 8.4%. Engineers India has the highest return on equity at 22.0%, while Alembic Pharmaceuticals has the fastest revenue growth at 8.4% a year. Prices are based on the 16 November 2026 close, and this article is educational, not investment advice.

Pharma, iron ore and consultancy stocks offer a focused view of a sector where demand keeps widening. Alembic Pharmaceuticals, NMDC and Engineers India cover a pharmaceuticals company, an iron ore miner and an engineering consultancy company.

This list covers three pharma, iron ore and consultancy stocks with complete current figures: Alembic Pharmaceuticals, NMDC and Engineers India. Every figure comes from the latest reported financials and the 16 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Pharma, Iron Ore and Consultancy Stocks?

Pharma, iron ore and consultancy stocks are listed companies that make and sell medicines for India and global markets, mine iron ore for steel makers, and provide engineering design and project management services for refineries and plants. Their earnings depend on medicine demand, steel demand and project spending.

Pharma, Iron Ore and Consultancy Stocks at a Glance

Company CMP (Rs) Market Cap (Rs Cr) P/E Industry P/E ROE (%) D/E
Alembic Pharmaceuticals 1,057.1 14,914 21.6 35.7 11.9 0.25
NMDC 68.92 61,921 8.3 9.9 21.9 0.19
Engineers India 312.05 15,096 19.2 22.7 22.0 0.01

On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing pharma, iron ore and consultancy stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Pharma, Iron Ore and Consultancy Stocks Have a Strong Roadmap in India?

Pharma, iron ore and consultancy stocks have a strong roadmap in India because wider access to quality medicines, steady steel production and steady project investment in energy and industry keep widening the market for these companies.

  • Pharmaceuticals. Patients need quality medicines.
  • Iron ore. Steel makers need steady ore supply.
  • Engineering consultancy. Plants need expert design and management.

Why Alembic Pharmaceuticals Features Among These Pharma, Iron Ore and Consultancy Stocks

Among the pharma, iron ore and consultancy stocks on this list, Alembic Pharmaceuticals is a Vadodara-based drug maker that sells generic formulations in the United States, branded medicines in India and active ingredients to other manufacturers.

Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%.

In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7.

Roadmap: The company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.

What to watch: Follow new approvals in the United States, the pace of complex generic launches and domestic growth.

Why NMDC Features Among These Pharma, Iron Ore and Consultancy Stocks

Among the drug maker, ore miner and project advisor shares on this list, NMDC is a public sector miner and India's largest producer of iron ore, with mines in Chhattisgarh and Karnataka, and it also has interests in lithium, diamonds and other minerals.

In the June 2026 quarter, revenue grew 1.5% year on year to Rs 7,143 crore, while net profit rose 1.9% to Rs 2,006 crore. Revenue rose from Rs 26,683 crore in FY22 to Rs 33,559 crore in FY26, a compound annual growth rate of 5.9%.

Net profit grew from Rs 5,538 crore in FY23 to Rs 7,415 crore in FY26, which works out to a compound annual growth rate of 10.2%. The company has a return on equity of 21.9%, a debt to equity ratio of 0.19 and a market capitalisation of Rs 61,921 crore. The stock trades at a P/E of 8.3, below the industry P/E of 9.9.

Roadmap: The company plans to raise production capacity to meet the country's growing steel demand and has a debt-free balance sheet that supports its mining expansion. Its low-cost iron ore and new mineral projects give it multiple growth options.

What to watch: Follow iron ore volumes and prices and the pace of its expansion and critical mineral projects.

Why Engineers India Features Among These Pharma, Iron Ore and Consultancy Stocks

Among the three companies on this list, Engineers India is a public sector engineering consultancy and project company that provides design, project management and construction services to oil, gas, petrochemical, fertiliser and infrastructure clients.

The company has a return on equity of 22.0%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 15,096 crore. The stock trades at a P/E of 19.2, below the industry P/E of 22.7.

Revenue rose from Rs 3,043 crore in FY22 to Rs 4,123 crore in FY26, a compound annual growth rate of 7.9%. Net profit grew from Rs 343 crore in FY22 to Rs 692 crore in FY26, which works out to a compound annual growth rate of 19.2%.

Roadmap: The company is involved in refinery expansions and new petrochemical projects and is widening its work in green energy, hydrogen and infrastructure. A debt-free balance sheet and a strong order book give it capacity to take on large mandates.

What to watch: Monitor order inflow from refinery and petrochemical projects and execution of existing mandates.

Alembic Pharmaceuticals vs NMDC vs Engineers India on Key Financials

The table below sets the three pharma, iron ore and consultancy stocks side by side on revenue, profit and margin, using reported figures.

Company FY22 Revenue (Rs Cr) FY26 Revenue (Rs Cr) Revenue CAGR (FY22-FY26) FY26 Net Profit (Rs Cr) FY26 Net Margin
Alembic Pharmaceuticals 5,356 7,399 8.4% 671 9.1%
NMDC 26,683 33,559 5.9% 7,415 22.1%
Engineers India 3,043 4,123 7.9% 692 16.8%

Engineers India posts the highest return on equity in this group at 22.0%. NMDC has the largest FY26 revenue at Rs 33,559 crore, and Alembic Pharmaceuticals shows the fastest revenue growth with a 8.4% compound annual rate. A useful habit with pharma, iron ore and consultancy stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Pharma, Iron Ore and Consultancy Stocks

Every theme carries risks that deserve a check before any decision. For these pharma, iron ore and consultancy stocks, the main points are: Long-term drug maker, ore miner and project advisor shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

  • Regulatory approvals. Plant inspections and approvals can affect supplies.
  • Commodity prices. Selling prices follow global and domestic markets.
  • Order timing. Project awards can shift between periods.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter pharma, iron ore and consultancy stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Pharma, Iron Ore and Consultancy Stocks

Pharma, iron ore and consultancy stocks reward patient research into demand, execution and financial strength. Alembic Pharmaceuticals, NMDC and Engineers India each have a clear plan to grow. Based on the 16 November 2026 close, Alembic Pharmaceuticals trades at Rs 1,057.1, NMDC at Rs 68.92 and Engineers India at Rs 312.05.

Download the Univest iOS App or Univest Android App to track pharma, iron ore and consultancy stocks, set price alerts and get research-backed stock ideas.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

What are pharma, iron ore and consultancy stocks?

Ans. Pharma, iron ore and consultancy stocks are listed companies that make and sell medicines for India and global markets, mine iron ore for steel makers, and provide engineering design and project management services for refineries and plants. Their earnings depend on medicine demand, steel demand and project spending. This list looks at three of them, Alembic Pharmaceuticals, NMDC and Engineers India, using reported FY22 to FY26 financials and the 16 November 2026 closing prices.

Which pharma, iron ore and consultancy stocks are covered in this list?

Ans. This list covers Alembic Pharmaceuticals, NMDC and Engineers India. Based on the 16 November 2026 close, Alembic Pharmaceuticals traded at Rs 1,057.1, NMDC at Rs 68.92 and Engineers India at Rs 312.05. Their return on equity ranges from 11.9% to 22.0%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.9% to 8.4%.

Why do pharma, iron ore and consultancy stocks have a strong future roadmap in India?

Ans. Pharma, iron ore and consultancy stocks have a strong roadmap in India because wider access to quality medicines, steady steel production and steady project investment in energy and industry keep widening the market for these companies. The main drivers are as follows. Pharmaceuticals. Patients need quality medicines. Iron ore. Steel makers need steady ore supply. Engineering consultancy. Plants need expert design and management. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Alembic Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7. Looking ahead, the company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.

How has NMDC performed financially?

Ans. Revenue rose from Rs 26,683 crore in FY22 to Rs 33,559 crore in FY26, a compound annual growth rate of 5.9%. Net profit grew from Rs 5,538 crore in FY23 to Rs 7,415 crore in FY26, which works out to a compound annual growth rate of 10.2%. In the June 2026 quarter, revenue grew 1.5% year on year to Rs 7,143 crore, while net profit rose 1.9% to Rs 2,006 crore. The company has a return on equity of 21.9%, a debt to equity ratio of 0.19 and a market capitalisation of Rs 61,921 crore. The stock trades at a P/E of 8.3, below the industry P/E of 9.9. Looking ahead, the company plans to raise production capacity to meet the country's growing steel demand and has a debt-free balance sheet that supports its mining expansion. Its low-cost iron ore and new mineral projects give it multiple growth options.

How has Engineers India performed financially?

Ans. Revenue rose from Rs 3,043 crore in FY22 to Rs 4,123 crore in FY26, a compound annual growth rate of 7.9%. Net profit grew from Rs 343 crore in FY22 to Rs 692 crore in FY26, which works out to a compound annual growth rate of 19.2%. The company has a return on equity of 22.0%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 15,096 crore. The stock trades at a P/E of 19.2, below the industry P/E of 22.7. Looking ahead, the company is involved in refinery expansions and new petrochemical projects and is widening its work in green energy, hydrogen and infrastructure. A debt-free balance sheet and a strong order book give it capacity to take on large mandates.

What risks should investors check before buying pharma, iron ore and consultancy stocks?

Ans. Investors should check a few risks before buying pharma, iron ore and consultancy stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Commodity prices. Selling prices follow global and domestic markets. Order timing. Project awards can shift between periods. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of pharma, iron ore and consultancy stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 16 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.

Recent Articles

Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.

Reviews

user-review-1
user-review-2
user-review-3
user-review-4
user-review-5

RESEARCH ANALYST

Get SEBI Registered
advice on the stocks
trending today.

Get 3 FREE Trade Ideas

+91
for Startups Accelerator 2024

for Startups Accelerator 2024

Trusted by 1Cr Indians

Trusted by 1Cr Indians

Awarded No.1 by Economic Times

Awarded No.1 by Economic Times

GET THE APP

Join 1Cr users today.

SEBI Registered Analyst-backed Picks. Free Demat. One App

  • Free Demat account in under 5 minutes
  • Live market data — Nifty, Sensex, sector insights
  • SEBI Registered analyst-backed stock picks
Get it on Google PlayDownload on the App Store
Stocks:
All|a|b|c|d|e|f|g|h|i|j|k|l|m|n|o|p|q|r|s|t|u|v|w|x|y|z

Copyright 2026 Univest. All rights reserved.
Designed with ❤️ in India

arrow down